Glutamol

Glutamol is an intravenous solution that contains the dipeptide alanyl glutamine as its active ingredient. While specific strength information is not disclosed, the product is marketed within the European Union as a nutritional supplement intended for parenteral administration. It provides a stable source of glutamine to support cellular metabolism, particularly in settings such as parenteral nutrition, intestinal mucosal support, and postoperative recovery and overall health.

Glutamol is employed in clinical practice primarily as a component of parenteral nutrition regimens and for supporting gastrointestinal integrity. It may also be considered during the postoperative period to aid tissue repair and maintain nitrogen balance.

- Supplementation of glutamine in patients receiving total parenteral nutrition. - Support of intestinal mucosal barrier function in critically ill or surgical patients. - Adjunctive therapy to promote recovery after major abdominal surgery. - Maintenance of nitrogen balance during periods of catabolic stress. - Provision of a readily available glutamine source for cellular energy metabolism.

While intravenous alanyl glutamine is generally well tolerated, some patients experience side effects ranging from mild discomfort to more serious systemic reactions. Monitoring during infusion helps identify and manage these events promptly.

Common: - Mild nausea or vomiting. - Transient headache. - Local infusion site irritation or erythema. - Slight increase in serum ammonia levels.

Serious: - Allergic hypersensitivity reactions, including rash or anaphylaxis. - Significant hyperammonemia in patients with hepatic impairment. - Electrolyte disturbances such as hyperkalemia. - Acute respiratory distress in rare cases.

When prescribing Glutamol, healthcare professionals should evaluate individual patient factors and adhere to standard infusion guidelines to minimize risk. Specific considerations are recommended for patients with organ dysfunction, metabolic disorders, or those receiving concurrent nutrition support.

- Assess renal and hepatic function before initiating therapy. - Adjust dosage in patients with severe liver disease or hyperammonemia risk. - Monitor serum electrolytes and ammonia levels during treatment. - Use aseptic technique to prevent catheter‑related infections. - Avoid rapid infusion rates that may cause circulatory overload. - Reevaluate need for continued supplementation daily in critically ill patients.

Alanyl glutamine may interact with other intravenously administered agents or conditions that affect nitrogen metabolism, requiring careful coordination with the treatment team. Awareness of these interactions helps prevent adverse outcomes and ensures optimal nutritional support.

Avoid: - Co‑administration with high‑dose ammonia‑producing medications in patients with liver failure. - Simultaneous infusion with incompatible solutions (e.g., calcium‑containing fluids) that may precipitate.

Use with caution: - Concurrent use of other amino acid or protein supplements that could alter nitrogen balance. - Patients receiving diuretics, due to potential electrolyte shifts. - Individuals on renal replacement therapy, requiring close monitoring of fluid and solute status.